Dendreon has had some ugly quarters before. In fact, earnings have generally been a house of pain for investors in the company. Most of the big stock drops seen since launching prostate cancer vaccine Provenge have coincided with disappointing sales results.
In this video, health-care analyst David Williamson, breaks down the company's first-quarter results and looks at how, despite warning investors that sales would declineÂ sequentially, even Dendreon's management appeared disappointed with the performance. Watch and find out what caused sluggish Provenge sales and whether Dendreon has a second life in it.
Resurgence, or dead cat bounce?
Shares of Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy by clicking here now.
The article Dendreon: Picking Through the Carnage originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid. The Motley Fool recommends Johnson & Johnson and owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.